Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Amplia Therapeutics Ltd. has announced a change in the director’s interest, with Dr. Robert Peach acquiring over a million ordinary shares and hundreds of thousands of listed options. The company is focused on developing Focal Adhesion Kinase (FAK) inhibitors, aimed at treating fibrotic cancers and chronic diseases like idiopathic pulmonary fibrosis. This acquisition reflects a strategic investment in Amplia’s promising pipeline, which could attract attention from investors interested in innovative cancer therapies.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue